Subscribe To
Perspective Therapeutics Reports First Quarter Fiscal 2023 Results
Additional CDMO capabilities added to increase availability of clinical trial product in the US Phase I/IIa studies are initiating in the first half of 2023 for VMT-α-NET for neuroendocrine tumors and VMT-01 for melanoma RICHLAND, WASHINGTON & CORALVILLE, IOWA, May 15, 2023 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a precision oncology company […] The post Perspective Therapeutics Reports First Quarter Fiscal 2023 Results appeared first on ForexTV...
Read More
Posted: May 16 2023, 00:22
Author Name: forextv
Views: 081599